← Back to Screener
Organogenesis Holdings Inc. Class A Common Stock (ORGO)
Price$2.52
Favorite Metrics
Price vs S&P 500 (26W)-45.62%
Price vs S&P 500 (4W)-4.89%
Market Capitalization$321.60M
P/E Ratio (Annual)8.68x
All Metrics
P/CF (Annual)28.67x
Book Value / Share (Quarterly)$3.42
P/TBV (Annual)1.55x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.76%
Cash Flow / Share (Quarterly)$-0.19
Price vs S&P 500 (YTD)-55.88%
Gross Margin (TTM)75.62%
Net Profit Margin (TTM)6.56%
EPS (TTM)$0.25
10-Day Avg Trading Volume3.75M
EPS Excl Extra (TTM)$0.25
Revenue Growth (5Y)10.77%
EPS (Annual)$0.28
ROI (Annual)8.12%
Gross Margin (Annual)75.62%
Net Profit Margin (5Y Avg)6.32%
Cash / Share (Quarterly)$0.74
P/E Basic Excl Extra (TTM)8.68x
Revenue Growth QoQ (YoY)78.13%
EPS Growth (5Y)12.99%
P/E Normalized (Annual)8.68x
ROA (Last FY)6.19%
Revenue Growth TTM (YoY)17.04%
EBITD / Share (TTM)$0.46
ROE (5Y Avg)11.11%
Operating Margin (TTM)7.92%
Cash Flow / Share (Annual)$-0.19
P/B Ratio0.74x
P/B Ratio (Quarterly)1.51x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)0.44x
Net Interest Coverage (TTM)-0.82x
ROA (TTM)7.27%
EPS Growth QoQ (YoY)423.65%
EV / EBITDA (TTM)4.17x
EPS Incl Extra (Annual)$0.28
Current Ratio (Annual)3.62x
Quick Ratio (Quarterly)3.14x
3-Month Avg Trading Volume1.21M
52-Week Price Return-41.18%
EV / Free Cash Flow (Annual)83.08x
P/E Incl Extra (TTM)8.68x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$3.35
P/S Ratio (Annual)0.57x
Asset Turnover (Annual)0.94x
52-Week High$7.08
Operating Margin (5Y Avg)6.13%
EPS Excl Extra (Annual)$0.28
CapEx CAGR (5Y)-4.36%
Tangible BV CAGR (5Y)29.75%
26-Week Price Return-36.87%
Quick Ratio (Annual)3.14x
13-Week Price Return-35.40%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)3.62x
Enterprise Value$250.146
Revenue / Share Growth (5Y)7.36%
Asset Turnover (TTM)1.11x
Book Value / Share Growth (5Y)24.47%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)4.92x
Pretax Margin (Annual)8.33%
Cash / Share (Annual)$0.74
3-Month Return Std Dev56.14%
Gross Margin (5Y Avg)75.87%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)12.32%
EBITDA Interim CAGR (5Y)24.16%
ROE (Last FY)8.53%
Net Interest Coverage (Annual)-6.05x
EPS Basic Excl Extra (Annual)$0.28
P/FCF (TTM)9.03x
Receivables Turnover (TTM)3.45x
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$0.25
Receivables Turnover (Annual)3.45x
ROI (TTM)9.39%
P/S Ratio (TTM)0.57x
Pretax Margin (5Y Avg)5.66%
Revenue / Share (Annual)$4.33
Tangible BV / Share (Annual)$3.35
Forward P/E21.65x
Price vs S&P 500 (52W)-76.27%
P/E Ratio (TTM)8.68x
EPS Growth TTM (YoY)3600.00%
Year-to-Date Return-51.74%
5-Day Price Return5.04%
EPS Normalized (Annual)$0.28
ROA (5Y Avg)6.46%
Net Profit Margin (Annual)6.56%
Month-to-Date Return5.49%
Cash Flow / Share (TTM)$0.20
EBITD / Share (Annual)$0.46
EPS Growth (3Y)34.40%
Operating Margin (Annual)7.92%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)8.89%
P/E Excl Extra (TTM)8.68x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.25
P/TBV (Quarterly)1.55x
P/B Ratio (Annual)1.51x
Inventory Turnover (TTM)4.92x
Pretax Margin (TTM)8.33%
Book Value / Share (Annual)$3.42
Price vs S&P 500 (13W)-38.27%
Net Margin Growth (5Y)5.25%
Beta1.40x
P/FCF (Annual)77.01x
Revenue / Share (TTM)$4.00
ROE (TTM)9.56%
52-Week Low$2.21
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.29
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ORGOOrganogenesis Holdings Inc. Class A Common Stock | 0.57x | 17.04% | 75.62% | 12.99% | $2.52 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Organogenesis is a regenerative medicine company specializing in advanced wound care, surgical, and sports medicine markets. The company develops and commercializes bioengineered tissue products designed to accelerate healing and improve surgical outcomes. Its portfolio includes solutions for chronic wound management, acute surgical applications, and soft tissue repair across hospital and outpatient settings.